ChiCTR1800019884 版本V1.0 版本创建时间2018/12/07 21:19:23 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1800019884 

最近更新日期:

Date of Last Refreshed on:

2018-12-07 21:17:36 

注册时间:

Date of Registration:

2018-12-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同剂量来曲唑对FET准备内膜促排卵的临床妊娠结局的影响随机对照临床试验

Public title:

The clinical pregant outcome of different doses of Letrozole used for endometrium preparation in non-PCOS women

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同剂量来曲唑对FET准备内膜促排卵的临床妊娠结局的影响随机对照临床试验

Scientific title:

The clinical pregant outcome of different doses of Letrozole used for endometrium preparation in non-PCOS women

研究课题代号(代码):

Study subject ID:

国家自然科学基金81801526

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

林嘉盈 

研究负责人:

汪云 

Applicant:

Jiaying Lin 

Study leader:

Yun Wang 

申请注册联系人电话:

Applicant telephone:

+86 021-53078108

研究负责人电话:

Study leader's telephone:

+86 021-53078108

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lemon_1114@126.com

研究负责人电子邮件:

Study leader's E-mail:

sammy20080228@icloud.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海制造局路639号

研究负责人通讯地址:

上海制造局路639号

Applicant address:

639 Zhizaoju Road, Shanghai, China

Study leader's address:

639 Zhizaoju Road, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第九人民医院

Applicant's institution:

Shanghai Ninth People's Hospital

研究负责人所在单位:

上海市第九人民医院

Affiliation of the Leader:

Shanghai Ninth People's Hospital

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第九人民医院

Primary sponsor:

Shanghai Ninth People's Hospital

研究实施负责(组长)单位地址:

上海制造局路639号

Primary sponsor's address:

639 Zhizaoju Road, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第九人民医院

具体地址:

上海制造局路639号

Institution
hospital:

Shanghai Ninth People's Hospital

Address:

639 Zhizaoju Road, Shanghai

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation of China (81801526)

Target disease:

infertility

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

III期临床试验 

Study phase:

3

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过一项前瞻性临床对照试验,研究不同剂量的来曲唑(2.5mg×3天及5mg×3天)在冷冻胚胎移植前准备内膜的临床效果及妊娠结局影响,以期优化内膜准备治疗方案。  

Objectives of Study:

To explore the effects of different doses of Letrozole on clinical pregnancy outcomes for endometrium preparation in women undergoing frozen–thawed embryo transfer

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1) 年龄20-40岁。
2) 移植胚胎中至少有1个优质胚胎。
3) 患者月经规律(30-40天);
4) 自愿加入本实验,并签署知情同意书。

Inclusion criteria

1. Aged between 20 and 40 years old;
2. Women have at least one good quality embyro;
3. Women with regular menstrual cycles;
4. Sign informed consent

排除标准:

1) 曾被诊断为子宫异常的女性;
2) 女方或男方染色体核型异常的患者(不包括染色体多态性);
3) 曾有复发性自然流产史的患者;
4) 患者对妊娠有明确影响的疾病的患者;
5) 在促排卵过程中出现卵巢过度刺激高风险的患者;
6) 不能依从本研究步骤者。

Exclusion criteria:

1. Women who have previously been diagnosed with a uterine abnormality;
2. Women or their partners with an abnormal chromosome karyotype not including chromosome polymorphisms;
3. Women who have experienced recurrent spontaneous abortions;
4. Women with chronic medical conditions that have confirmed effects on pregnancy;
5. Women who has high risk of ovarian hyperstimulation syndrome (OHSS) during controlled ovarian hyperstimulation;
6. Women who are unable to comply with the study procedures.

研究实施时间:

Study execute time:

From 2019-01-01 00:00:00 To 2020-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-01-01 00:00:00 To 2019-12-31 00:00:00  

干预措施:

Interventions:

组别:

Group 2

样本量:

150

Group:

Group 2

Sample size:

干预措施:

来曲唑低剂量组

干预措施代码:

Intervention:

low Letrozole group

Intervention code:

组别:

Group 1

样本量:

150

Group:

Group 1

Sample size:

干预措施:

来曲唑高剂量

干预措施代码:

Intervention:

high dose Letrozole

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

测量指标:

Outcomes:

指标中文名:

活产率

指标类型:

主要指标

Outcome:

live birth rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 40 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

计算机软件产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The random number sequence will be generated by computer software

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Not stated

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Not stated

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not stated

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2018-12-07 21:17:36